Syndax deal could unlock GvHD combos, new diseases for Incyte
Addition of anti-CSFR1 axatilimab complements Jakafi in Incyte’s portfolio
A deal with Syndax gives Incyte a therapy with a differentiated mechanism of action in the changing marketplace for chronic graft-versus-host disease drugs, complementing Jakafi in Incyte’s portfolio and potentially setting up the company to develop wholly-owned, steroid-sparing combination regimens.
The deal closely follows the $1.9 billion takeout of Kadmon Holdings Inc. (NASDAQ:KDMN) by Sanofi (Euronext:SAN; NASDAQ:SNY), which gave the French pharma newly approved drug Rezurock belumosudil for chronic GvHD. The companies are all aiming for a market that Briggs Morrison, CEO of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX), characterized last month as “evolving.” FDA approved Jakafi for the indication last week...